Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2015-08-12 Interim / Quarterly Rep…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
H1 Präsentation
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Evotec AG, H1 2015 Interim Report' and contains detailed financial performance data, including revenue growth, EBITDA, liquidity, and a breakdown of business segments (EVT Execute and EVT Innovate). It provides a comprehensive review of the company's activities for the first half of the fiscal year, which fits the definition of an Interim/Quarterly Report (IR). H1 2015
2015-08-12 English
Evotec, Apeiron Biologics and Sanofi jointly develop novel small molecule-based cancer immunotherapies
Regulatory Filings Classification · 100% confidence The document is a news release dated August 10, 2015, announcing a strategic collaboration between Evotec AG, Apeiron Biologics, and Sanofi regarding cancer immunotherapies. It details the terms, objectives, and involved parties. The text ends with a distribution notice from DGAP, stating it is a 'Corporate News' and mentioning 'Regulatory Announcements, Financial/Corporate News and Press Releases'. Since this is an announcement of a significant business development (a strategic alliance/collaboration) and not a formal periodic financial report (like 10-K or IR), nor a specific shareholder action (like DIV or DVA), it fits best under the general category for corporate news that doesn't fit elsewhere, which is Regulatory Filings (RNS), as it is disseminated via a regulatory news service (DGAP). It is not a Call Transcript (CT), Earnings Release (ER), or a specific financial filing.
2015-08-10 English
Sanofi and Evotec align forces to develop next generation therapies in diabetes
Regulatory Filings Classification · 100% confidence The document is a press release dated August 7, 2015, announcing a strategic collaboration (alliance) between Evotec AG and Sanofi regarding diabetes therapies. It details the nature of the collaboration, financial terms (upfront payment, milestones, royalties), and includes quotes from management. The distribution information at the end mentions 'DGAP - a service of EQS Group AG' and categorizes the dissemination as 'Corporate News' and 'Press Releases'. This content is a specific business announcement regarding a partnership, not a mandatory periodic financial report (like 10-K or IR), a formal audit report (AR), or a transcript (CT). It is a corporate news item detailing a significant business development. Since there is no specific category for 'Partnership Announcement', and it is a general corporate news item distributed via a regulatory news service (DGAP), the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory announcements that are not covered by more specific codes like ER or CAP. However, given the nature of the announcement (a major strategic alliance with financial implications), it is a significant corporate event announcement. If 'Partnership Announcement' were an option, it would fit best. Among the provided options, RNS is the best fit for a general, non-periodic corporate news release distributed via a regulatory feed, although it is not strictly a regulatory filing in the SEC sense, but rather a market disclosure.
2015-08-07 English
Evotec to report first half-year 2015 results on 12 August 2015
Report Publication Announcement Classification · 99% confidence The document is a press release dated August 5, 2015, announcing that Evotec AG will report its financial results for the first half of 2015 on August 12, 2015. It provides details for an accompanying conference call and webcast. This is not the actual financial report (which would be an IR or AR), but rather an announcement about the upcoming release of results and a call to discuss them. This fits the definition of a Report Publication Announcement (RPA), which signals the timing and details of a forthcoming report release, or potentially an Earnings Release (ER) if it contained the actual summary results, but since it only announces the date of the results release, RPA is more precise for this pre-announcement. Given the options, RPA (Report Publication Announcement) is the best fit as it announces the publication of the H1 2015 results.
2015-08-05 English
Q1 Präsentation
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Evotec AG, First Quarter Report 2015' and contains detailed financial highlights, business strategy updates, and operational performance metrics for the first quarter of 2015. It includes specific financial data such as revenue growth, EBITDA figures, and liquidity positions. As it provides substantive financial analysis and results for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2015
2015-07-29 English
Evotec enters innovative research initiative with Gladstone Institutes and Dolby Family Ventures in Alzheimer's Disease
Regulatory Filings Classification · 100% confidence The document is a press release dated July 24, 2015, announcing a new research initiative between Evotec AG, Gladstone Institutes, and Dolby Family Ventures concerning Alzheimer's disease. It uses standard press release formatting, including a headline, date, company boilerplate information, and a 'Contact' section. The key indicator is the distribution tag: 'Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.' This structure strongly suggests a general corporate announcement that is not a formal regulatory filing like a 10-K, a specific financial report (ER, IR), or a shareholder communication (DEF 14A, AGM-R). Since it details a strategic business development (alliance/partnership) and does not fit into the more specific categories like M&A (TAR) or Capital Change (CAP), it falls best under the general Regulatory Filings/Announcements category, which serves as a fallback for significant, non-standard news releases. Given the options, RNS (Regulatory Filings) is the most appropriate general category for this type of news release distributed via a service like DGAP, especially when the content is not a specific financial report or insider transaction.
2015-07-24 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.